59101-28-9

Basic information

• Product Name: 16-Bromohexadecanol
• Synonyms: 1-Hexadecanol, 16-bromo-;16-BROMO-HEXADECAN-1-OL;16-BROMOHEXADECANOL;16-BROMO-1-HEXADECANOL;1-Bromohexadecane-16-ol
• CAS NO: 59101-28-9
• Molecular Formula: C₁₆H₃₃BrO
• Molecular Weight: 321.34
• Product Categories: pharmacetical
• Mol File: 59101-28-9.mol
• Article Data: 26

Chemical Properties

• Melting Point: 45-52°C
• Boiling Point: 383.7 °C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.059 g/cm³
• Vapor Pressure: 1.81E-07mmHg at 25°C
• Refractive Index: 1.475
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 15.20±0.10(Predicted)
• CAS DataBase Reference: 16-Bromohexadecanol(CAS DataBase Reference)
• NIST Chemistry Reference: 16-Bromohexadecanol(59101-28-9)
• EPA Substance Registry System: 16-Bromohexadecanol(59101-28-9)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 59101-28-9(Hazardous Substances Data)

Usage

General Description

16-Bromohexadecanol is a chemical compound with the molecular formula C16H33BrO. It is a long-chain alcohol with a bromine atom attached to the hexadecyl group. 16-Bromohexadecanol is commonly used as an intermediate in the synthesis of various organic compounds and can also be used as a surfactant or emulsifier in industrial applications. It is a white solid at room temperature and has a characteristic odor. 16-Bromohexadecanol may also have potential applications in the field of pharmaceuticals, cosmetics, and materials science due to its unique chemical properties. However, it is important to handle this compound with care and follow proper safety precautions, as it may pose hazards if not handled properly.

InChI:InChI=1/C16H33BrO/c17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18/h18H,1-16H2

Upstream product

• 26825-89-8 methyl 16-bromohexadecanoate 
• 7735-42-4 1,16-hexadecanediol 
• 109-29-5 15-hexadecanolide 
• 21964-51-2 hexadeca-1,15-diene 
• 505-54-4 thapsic acid 
• 7370-44-7 5-hexadecanolide 
• 36575-67-4 16-hydroxyhexadecanoic acid methyl ester 
• 2536-35-8 16-bromohexadecanoic acid 

Downstream Products

• 109183-03-1 (E)-But-2-enedioic acid 16-bromo-hexadecyl ester ethyl ester 
• 651034-07-0 16-bromohexadecanal 
• 153076-22-3 16-(dimethylamino)-1-hexadecanol 
• 69506-08-7 17-(p-Methoxyphenyl)heptadecan-1-ol 
• 907218-89-7 16-(2,5-dimethoxyphenoxy)hexadecan-1-ol 
• 913343-13-2 16-tritylsulfanyl-hexadecan-1-ol 
• 887604-07-1 octadec-17-ynyloxymethyl-benzene 
• 887604-27-5 Q₂FA₁₈ 
• 887604-32-2 Q₃FA₁₈ 
• 887604-12-8 2-(18-Benzyloxy-octadec-1-ynyl)-1,4-dimethoxy-benzene 
• 887604-17-3 1-(18-Benzyloxy-octadec-1-ynyl)-2,4,5-trimethoxy-benzene 
• 887604-22-0 1-(18-Benzyloxy-octadec-1-ynyl)-2,3,4,5-tetramethoxy-benzene 
• 1151988-78-1 C₂₇H₅₃N₂O₃PS 
• 1151988-75-8 C₁₈H₃₆O₂S 

Relevant articles and documents

Pachychalines A-C: Novel 3-alkylpyridinium salts from the marine sponge Pachychalina sp.

Three 3-alkylpyridinium salts, pachychalines A (1), B (2) and C (3), were isolated from the Caribbean marine sponge Pachychalina sp. (order Haplosclerida). They are the first examples of 3-(aminoalkyl)pyridinium salts. Their chemical structures were elucidated by NMR spectroscopy and detailed ESI HRMS-MS analysis. The total synthesis of 1 allowed the confirmation of the unusual C-C connection between both pyridinium moieties. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

Scalable Synthesis of Human Ultralong Chain Ceramides

Ceramides with ultralong chains (≥30 carbons), also known as acylceramides, play a critical role in the survival of mammals on dry land. An efficient and scalable synthesis of four major classes of ultralong human skin ceramides is reported. The key approach involves the use of a succinimidyl ester that acts as a protective group, helps overcome the extremely low solubility, and simultaneously activates the fatty acid for its clean and high-yielding attachment to a sphingoid base.

Synthesis of new ligands for targeting the S1P1 receptor

Sphingosine-1-phosphate (S1P) influences various fundamental biological processes by interacting with a family of five G protein-coupled receptors (S1P1-5). FTY720, a sphingosine analogue, which was approved for treatment of relapsing forms of multiple sclerosis, is phosphorylated in vivo and acts as an agonist of four of the five S1P receptor subtypes. Starting from these lead structures we developed new agonists for the S1P1 receptor. The biological activity was tested in vivo and promising ligands were fluorinated at different positions to identify candidates for positron emission tomography (PET) imaging after [18F]-labelling. The radioligands shall enable the imaging of S1P1 receptor expression in vivo and thus may serve as novel imaging markers of S1P-related diseases.